Citron Research says Valeant Pharma (VRX) has better chance than HLF of 'going to $0'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday
November 1, 2015 7:32 PM ESTCitron Research's Andrew Left is dialing back on what investors should expect when he updates his report on battered Valeant Pharma (NYSE: VRX) on Monday.
During Bill Ackman's 4-hour defense of Valeant on Friday, short seller Left tweeted: "$VRX has a... More
Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
October 30, 2015 12:57 PM EDTThe bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.
This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More
Citron's Left Will be on CNBC Monday to Talk About Valeant (VRX)
October 30, 2015 12:27 PM EDTCitron's Andrew Left will be back on CNBC's Halftime Report on Monday, November 2nd, to talk about his upcoming report on Valeant Pharma (NYSE: VRX).
... More